Gene Transfer of Kringle 1-5 Suppresses Tumor Development and Improves Prognosis of Mice With Hepatocellular Carcinoma

Gastroenterology

Volumn 130, Issue 4, 2006, Pages 1301-1310

  Torimura, Takuji ^a   Ueno, Takato ^a   Kin, Motoaki ^a   Taniguchi, Eitaro ^a   Nakamura, Toru ^a   Inoue, Kinya ^a   Sakata, Ryuichiro ^a   Hashimoto, Osamu ^a   Sakamoto, Masaharu ^a   Ohira, Hiromasa ^c   Kumashiro, Ryukichi ^a   Sata, Michio ^a   Yano, Hirohisa ^b   Kojiro, Masamichi ^b   Veitonmaki, Niina ^d   Cao, Yihai ^d  

^a Center of the 21st Century Center   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; CHOLESTEROL; COMPLEMENTARY DNA; LIPOSOME; PROTEIN; PROTEIN KRINGLE 1-5; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL; BODY WEIGHT; CANCER INHIBITION; CANCER SURVIVAL; CAPILLARY ENDOTHELIUM; CELL PROLIFERATION; CONTROLLED STUDY; COW; DENSITY; DOSE RESPONSE; DRUG PURIFICATION; ENDOTHELIUM CELL; GENE TRANSFER; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER METASTASIS; MALE; MOUSE; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; NONVIRAL GENE THERAPY; NUDE MOUSE; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH; WESTERN BLOTTING;

EID: 33646002668     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.02.020     Document Type: Article

References (32)

1. Di Bisceglie A.M., Rustgi V.K., Hoofnagle J.H., Dusheiko G.M., and Lotze M.T. NIH conference. Hepatocellular carcinoma. Ann Intern Med 108 (1988) 390-401
2. Honda H., Tajima T., Kajiyama K., Kuroiwa T., Yoshimitsu K., Irie H., Aibe H., Shimada M., and Masuda K. Vascular changes in hepatocellular carcinoma. correlation of radiologic and pathologic findings. AJR Am J Roentgenol 173 (1999) 1213-1217
3. Matsui O., Kadoya M., Kameyama T., Yoshikawa J., Takashima T., Nakanuma Y., Unoura M., Kobayashi K., Izumi R., Ida M., et al. Benign and malignant nodules in cirrhotic livers. distinction based on blood supply. Radiology 178 (1991) 493-497
4. Saaristo A., Karpanen T., and Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 19 (2000) 6122-6129
5. Folkman J., and D'Amore P.A. Blood vessel formation. what is its molecular basis?. Cell 87 (1996) 1153-1155
6. Kirsch M., Schackert G., and Black P.M. Metastasis and angiogenesis. Cancer Treat Res 117 (2004) 285-304
7. Li X.M., Tang Z.Y., Zhou G., Lui Y.K., and Ye S.L. Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 17 (1998) 13-17
8. Holmgren L., O'Reilly M.S., and Folkman J. Dormancy of micrometastases. balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1 (1995) 149-153
9. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., and Folkman J. Angiostatin. a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
10. Cao Y., and Xue L. Angiostatin. Semin Thromb Hemost 30 (2004) 83-93
11. Cao Y., Ji R.W., Davidson D., Schaller J., Marti D., Sohndel S., McCance S.G., O'Reilly M.S., Llinas M., and Folkman J. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 271 (1996) 29461-29467
12. Cao Y., Cao R., and Veitonmaki N. Kringle structures and antiangiogenesis. Curr Med Chem Anticancer Agents 2 (2002) 667-681
13. Cao Y., Chen A., An S.S., Ji R.W., Davidson D., and Llinas M. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 272 (1997) 22924-22928
14. Cao R., Wu H.L., Veitonmaki N., Linden P., Farnebo J., Shi G.Y., and Cao Y. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci U S A 96 (1999) 5728-5733
15. Chen Q.R., Kumar D., Stass S.A., and Mixson A.J. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 59 (1999) 3308-3312
16. Sauter B.V., Martinet O., Zhang W.J., Mandeli J., and Woo S.L. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci U S A 97 (2000) 4802-4807
17. Templeton N.S., and Lasic D.D. New direction in liposome gene delivery. Mol Biotechnol 11 (1999) 175-180
18. Templeton N.S., Lasic D.D., Frederik P.M., Strey H.H., Roberts D.D., and Pavlakis G.N. Improved DNA. liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 15 (1997) 647-652
19. Cao Y., O'Reilly M.S., Marshall B., Flynn E., Ji R.W., and Folkman J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 101 (1998) 1055-1063
20. Maeshima S., Sudhakar A., Lively J.C., Veki K., Kharbanda S., Kahn C.R., Sonenberg N., Hynes R.O., and Kalluri R. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295 (2002) 140-143
21. Volpert U.V., Lawler J., and Bouck N.P. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastasis via thrombospondin-1. Proc Natl Acad Sci U S A 95 (1998) 6343-6348
22. Tarui T., Miles L.A., and Takada Y. Specific interaction of angiostatin with integrin alpha v beta 3 in endothelial cells. J Biol Chem 276 (2001) 39562-39568
23. Veitonmaki N., Cao R., Wu L.H., Moser T.L., Li B., Pizzo S.V., Zhivotovsky B., and Cao Y. Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced antiangiogenesis. Cancer Res 64 (2004) 3679-3686
24. Ishikawa H., Nakao K., Matsumoto K., Ichikawa T., Hamasaki K., Nakata K., and Eguchi K. Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene. Hepatology 37 (2003) 696-704
25. Sacco M.G., Cato E.M., Ceruti R., Soldati S., Indraccolo S., Caniatti M., Scanziani E., and Vezzoni P. Systemic gene therapy with anti-angiogenic factors inhibits spontaneous breast tumor growth and metastasis in MMTVneu transgenic mice. Gene Ther 8 (2001) 67-70
26. O'Reilly M.S., Holmgren L., Chen C., and Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2 (1996) 689-692
27. Matsumoto K., Ishikawa H., Nishimura D., Hamasaki K., Nakao K., and Eguchi K. Antiangiogenic property of pigment epithelium-derived factor in hepatocellular carcinoma. Hepatology 40 (2004) 252-259
28. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy. a new paradigm for combination therapy. Nat Med 7 (2001) 987-989
29. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., Yancopoulos G.D., and Wiegand S.J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284 (1999) 1994-1998
30. Hsieh J.L., Wu C.L., Lai M.D., Lee C.H., Tsai C.S., and Shiau A.L. Gene therapy for bladder cancer using E1B-55 kD-deleted adenovirus in combination with adenoviral vector encoding plasminogen kringles 1-5. Br J Cancer 88 (2003) 1492-1499
31. Kin M., Torimura T., Ueno T., Nakamura T., Ogata R., Sakamoto M., Tamaki S., and Sata M. Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats. Int J Oncol 16 (2000) 375-382
32. Yoshiji H., Kuriyama S., Yoshii J., Yamazaki M., Kikukawa M., Tsujinoue H., Nakatani T., and Fukui H. Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 28 (1998) 1489-1496